Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma-Reference-Cited by-同舟云学术

Incidence and management of bevacizumab-associated gastrointestinal perforations in patients with recurrent ovarian carcinoma

Published:2010-03 Issue:3 Volume:116 Page:335-339
ISSN:0090-8258
Container-title:Gynecologic Oncology
language:en
Short-container-title:Gynecologic Oncology

Author:

Diaz John P.,Tew William P.,Zivanovic Oliver,Konner Jason,Sabbatini Paul J.,dos Santos Lisa A.,Abu-Rustum Nadeem R.,Chi Dennis S.,Aghajanian Carol,Barakat Richard R.

Publisher

Elsevier BV

Subject

Obstetrics and Gynecology,Oncology

Reference28 articles.

1. Cancer statistics, 2009;Jemal;CA Cancer J. Clin.,2009

2. A reassessment of the role of second-look laparotomy in advanced ovarian cancer;Ho;J. Clin. Oncol.,1987

3. Prognostic factors for outcome of and survival after second-look laparotomy in patients with advanced ovarian carcinoma;Lund;Obstet. Gynecol.,1990

4. The prognostic significance of angiogenesis in epithelial ovarian carcinoma;Alvarez;Clin. Cancer Res.,1999

5. Prognostic and predictive value of tumour angiogenesis in ovarian carcinomas;Gasparini;Int. J. Cancer,1996

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Malignant ascites: Current therapy options and treatment prospects;Cancer Treatment Reviews;2023-12

2. Safety Analysis of Bevacizumab in Ovarian Cancer Patients;Journal of Clinical Medicine;2023-03-06

3. Targeted therapy and molecular genetics;DiSaia and Creasman Clinical Gynecologic Oncology;2023

4. REZOLVE (ANZGOG-1101): A phase 2 trial of intraperitoneal bevacizumab to treat symptomatic ascites in patients with chemotherapy-resistant, epithelial ovarian cancer;Gynecologic Oncology;2021-05

5. Extreme complications related to bevacizumab use in the treatment of ovarian cancer: a case series from a III level referral centre and review of the literature;Annals of Translational Medicine;2020-12